Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
SWOG S2213
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
- NCT06022939 ↗
- Recruiting
- SWOG Cancer Research Network
- Deep
We haven't built an HCP commentary report on SWOG S2213 (melphalan, bortezomib and 3 more in AL Amyloidosis) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SWOG S2213 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 72 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients With Newly Diagnosed AL Amyloidosis
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- AL Amyloidosis
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation; Biopsy; Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Bortezomib; Computed Tomography; Cyclophosphamide; Daratumumab and Hyaluronidase-fihj; Dexamethasone; Echocardiography; Magnetic Resonance Imaging; Melphalan; Positron Emission Tomography; Stem Cell Isolation; Survey Administration
- Arms
- Consolidation Arm I (Chemotherapy) · Active comparator
- Consolidation Arm II (Chemotherapy, ASCT) · Experimental
- Induction (Chemotherapy) · Experimental
- Maintenance (daratumumab and hyaluronidase-fihj) · Experimental
- Enrollment
- 338 (estimated)
- Primary outcomes
- Major organ deterioration progression-free survival (PFS)
- Sponsor
- SWOG Cancer Research Network with National Cancer Institute (NCI)
- Start
- Jul 1, 2024
- Primary completion
- Jul 29, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT06022939 · updated May 6, 2026